HUP0004034A3 - Kay - a novel immune system protein - Google Patents

Kay - a novel immune system protein

Info

Publication number
HUP0004034A3
HUP0004034A3 HU0004034A HUP0004034A HUP0004034A3 HU P0004034 A3 HUP0004034 A3 HU P0004034A3 HU 0004034 A HU0004034 A HU 0004034A HU P0004034 A HUP0004034 A HU P0004034A HU P0004034 A3 HUP0004034 A3 HU P0004034A3
Authority
HU
Hungary
Prior art keywords
kay
immune system
system protein
novel immune
novel
Prior art date
Application number
HU0004034A
Other languages
Hungarian (hu)
Original Assignee
Apotech R & D Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotech R & D Sa filed Critical Apotech R & D Sa
Publication of HUP0004034A2 publication Critical patent/HUP0004034A2/en
Publication of HUP0004034A3 publication Critical patent/HUP0004034A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
HU0004034A 1997-09-12 1998-09-11 Kay - a novel immune system protein HUP0004034A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Publications (2)

Publication Number Publication Date
HUP0004034A2 HUP0004034A2 (en) 2001-03-28
HUP0004034A3 true HUP0004034A3 (en) 2002-08-28

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004034A HUP0004034A3 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Country Status (17)

Country Link
EP (1) EP1012270A2 (en)
JP (1) JP2001515711A (en)
KR (1) KR20010023892A (en)
CN (1) CN1269832A (en)
AU (1) AU9315298A (en)
BR (1) BR9812433A (en)
CA (1) CA2303424A1 (en)
EA (1) EA200000311A1 (en)
EE (1) EE200000148A (en)
HU (1) HUP0004034A3 (en)
IL (1) IL134480A0 (en)
IS (1) IS5375A (en)
NO (1) NO20001240L (en)
PL (1) PL339740A1 (en)
SK (1) SK3532000A3 (en)
TR (1) TR200000654T2 (en)
WO (1) WO1999012964A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
CA2310987A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
WO1999033980A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
PL198934B1 (en) 1999-01-25 2008-08-29 Apoxis Sa Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
EP1860190A3 (en) * 1999-02-23 2008-03-12 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variants
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AU4986700A (en) * 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
PL207501B1 (en) 1999-08-17 2010-12-31 Apotech R & D Sa Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
AU2001234953B2 (en) 2000-02-11 2006-03-16 Biogen Ma Inc. Heterologous polypeptide of the tnf family
DE60028830T2 (en) 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco ANTI-APRIL ANTIBODIES AND HYBRIDOMA CELLS
ATE361318T1 (en) 2000-05-12 2007-05-15 Amgen Inc POLYPEPTIDES THAT INHIBIT APRIL-MEDIATED ACTIVATION OF T AND B CELLS
NZ522700A (en) 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002018620A2 (en) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
NZ529267A (en) 2001-05-11 2006-05-26 Amgen Inc Peptides and related molecules that bind to tall-1
AR035119A1 (en) 2001-08-16 2004-04-14 Lilly Co Eli ANTI-HTNFSF13B HUMAN ANTI-BODIES
JP5524441B2 (en) 2003-03-28 2014-06-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド Shortened BAFF receptor
NZ543712A (en) 2003-06-05 2008-06-30 Genentech Inc Combination therapy for B cell disorders
EP1675609A1 (en) 2003-10-20 2006-07-05 Biogen Idec MA Inc. Therapeutic regimens for baff antagonists
EP1709072A1 (en) * 2004-01-29 2006-10-11 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
RU2411956C2 (en) 2004-10-05 2011-02-20 Дженентек, Инк. Method of treating vasculitis
WO2006044582A2 (en) 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
WO2006067210A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
EP1922080A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
EP1922079A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1952150B1 (en) 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
AR060935A1 (en) 2006-05-15 2008-07-23 Ares Trading Sa METHODS TO TREAT AUTOIMMUNE DISEASES USING A TACI-IG FUSION MOLECULA
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2011028945A1 (en) 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
CN103502472B (en) 2011-02-28 2017-06-06 弗·哈夫曼-拉罗切有限公司 Biomarker and the method for predicting the response to B cell antagonists
CN111848796A (en) 2013-02-05 2020-10-30 英格玛布有限责任公司 Method for selecting antibodies against BCMA
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
WO2015155332A1 (en) 2014-04-11 2015-10-15 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155103A1 (en) * 1993-02-03 1994-08-18 Rudolph Lucas Tnf-alpha muteins and a process for preparing them
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
CA2266439C (en) * 1996-10-25 2009-06-16 Human Genome Sciences, Inc. Neutrokine .alpha.
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5

Also Published As

Publication number Publication date
WO1999012964A2 (en) 1999-03-18
CN1269832A (en) 2000-10-11
CA2303424A1 (en) 1999-03-18
NO20001240D0 (en) 2000-03-09
IL134480A0 (en) 2001-04-30
WO1999012964A3 (en) 1999-05-27
IS5375A (en) 2000-02-11
SK3532000A3 (en) 2001-12-03
HUP0004034A2 (en) 2001-03-28
TR200000654T2 (en) 2000-07-21
EA200000311A1 (en) 2000-10-30
AU9315298A (en) 1999-03-29
BR9812433A (en) 2000-09-26
JP2001515711A (en) 2001-09-25
KR20010023892A (en) 2001-03-26
EP1012270A2 (en) 2000-06-28
EE200000148A (en) 2001-02-15
NO20001240L (en) 2000-05-10
PL339740A1 (en) 2001-01-02

Similar Documents

Publication Publication Date Title
HUP0004034A3 (en) Kay - a novel immune system protein
IL121454A0 (en) Internet-telephone interface system
ZA9710338B (en) Proteins
GB9510830D0 (en) Proteins
GB9703681D0 (en) Protein complemention
GB9719879D0 (en) Protein
EP1018551A4 (en) Megsin protein
ZA984322B (en) Sucrose-binding proteins
GB9715064D0 (en) Protein expression
GB9720784D0 (en) Protein
GB9519865D0 (en) Protein
GB9622436D0 (en) Protein
EP0915100A4 (en) Novel protein
GB9722110D0 (en) Conveyor system
GB9604865D0 (en) Modified proteins
GB9706119D0 (en) Novel protein
GB9714075D0 (en) Novel protein
GB9704252D0 (en) Novel protein
GB9703850D0 (en) Novel protein
GB9703827D0 (en) Novel protein
GB9619879D0 (en) Immune system invigorator
GB9719670D0 (en) Protein
GB9703103D0 (en) Protein
GB9720785D0 (en) Protein
GB9722003D0 (en) Proteins